Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England

Fox, Christopher P.; Townsend, William; Gribben, John G.; Menne, Tobias; Kalakonda, Nagesh; Williams, Paula; Toron, Farah; Tyas, Emma; Cooper, Miranda; Rickards, Joshua; Radford, John

Abstract

Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression-free survival (PFS) and event-free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.

Citation

Fox, C. P., Townsend, W., Gribben, J. G., Menne, T., Kalakonda, N., Williams, P., Toron, F., Tyas, E., Cooper, M., Rickards, J., & Radford, J. (2024). Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England. eJHaem, 5(5), 992-997. https://doi.org/10.1002/jha2.970

• Journal Article Type: Article
• Acceptance Date: Jun 10, 2024
• Online Publication Date: Aug 7, 2024
• Publication Date: 2024-10
• Deposit Date: Dec 2, 2024
• Publicly Available Date: Dec 2, 2024
• Journal: eJHaem
• Electronic ISSN: 2688-6146
• Publisher: Wiley
• Peer Reviewed: Peer Reviewed
• Volume: 5
• Issue: 5
• Pages: 992-997
• DOI: https://doi.org/10.1002/jha2.970
• Public URL: https://nottingham-repository.worktribe.com/output/38118156
• Publisher URL: https://onlinelibrary.wiley.com/doi/10.1002/jha2.970